Related references
Note: Only part of the references are listed.Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Epidermal Growth Factor Receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer
Yasushi Yatabe et al.
CANCER RESEARCH (2008)
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Fred R. Hirsch et al.
CLINICAL CANCER RESEARCH (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer A Literature Review
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer
Takashi Sone et al.
CANCER (2007)
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S7681 and V769L
Hajime Asahina et al.
LUNG CANCER (2006)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
Emiliano Calvo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
SW Han et al.
CLINICAL CANCER RESEARCH (2006)
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
YR Chen et al.
ONCOGENE (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Ethnic and racial differences in the smoking-related risk of lung cancer
CA Haiman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
Marileila Varella-Garcia
DIAGNOSTIC PATHOLOGY (2006)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology
PA Jänne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer
SH Yang et al.
CLINICAL CANCER RESEARCH (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
SF Huang et al.
CLINICAL CANCER RESEARCH (2004)
Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
T Kosaka et al.
CANCER RESEARCH (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Impact of race in lung cancer - Analysis of temporal trends from a surveillance, epidemiology, and end results database
SM Gadgeel et al.
CHEST (2001)
Interval estimation for a binomial proportion - Comment - Rejoinder
LD Brown et al.
STATISTICAL SCIENCE (2001)
Share Paper
